Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Becton Dickinson v. Quidel

This article was originally published in The Gray Sheet

Executive Summary

Becton Dickinson v. Quidel: Firms reach settlement agreement on a patent infringement suit alleging that several Quidel products infringe on two Becton Dickinson patents for analytical chemistry tests ("The Gray Sheet" April 14, In Brief). Under the terms of the agreement Quidel will pay a cash license fee and royalties on net sales of the products beginning April 1, 1997. Quidel also will license its Q-Label technology to BD in exchange for royalties on future sales. Noting that it "has opportunities to mitigate the impact" of the additional expense through sales growth and improved margins, Quidel estimates that the annual cost of the settlement to the firm will be approximately $1.9 mil. Quidel continues to maintain that its products to not infringe the BD patents...

You may also be interested in...

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts